These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 30581001)
21. Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562. Li N; Chen Q; Gu J; Li S; Zhao G; Wang W; Wang Z; Wang X Oncotarget; 2017 May; 8(22):36517-36530. PubMed ID: 28388554 [TBL] [Abstract][Full Text] [Related]
22. APOA5 alleviates reactive oxygen species to promote oxaliplatin resistance in PIK3CA-mutated colorectal cancer. Liu YL; Xiang Z; Zhang BY; Zou YW; Chen GL; Yin L; Shi YL; Xu LL; Bi J; Wang Q Aging (Albany NY); 2024 Jun; 16(11):9410-9436. PubMed ID: 38848145 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related ( Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998 [TBL] [Abstract][Full Text] [Related]
24. Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells. Li L; Liu W; Sun Q; Zhu H; Hong M; Qian S Oxid Med Cell Longev; 2021; 2021():8877460. PubMed ID: 33532040 [TBL] [Abstract][Full Text] [Related]
25. Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells. Vijayaraghavalu S; Labhasetwar V Drug Deliv Transl Res; 2018 Oct; 8(5):1289-1299. PubMed ID: 29947019 [TBL] [Abstract][Full Text] [Related]
26. Evaluation for Synergistic Effects by Combinations of Photodynamic Therapy (PDT) with Temoporfin (mTHPC) and Pt(II) Complexes Carboplatin, Cisplatin or Oxaliplatin in a Set of Five Human Cancer Cell Lines. Lange C; Bednarski PJ Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332729 [TBL] [Abstract][Full Text] [Related]
27. Enhancement of oxaliplatin-induced colon cancer cell apoptosis by alantolactone, a natural product inducer of ROS. Cao P; Xia Y; He W; Zhang T; Hong L; Zheng P; Shen X; Liang G; Cui R; Zou P Int J Biol Sci; 2019; 15(8):1676-1684. PubMed ID: 31360110 [TBL] [Abstract][Full Text] [Related]
28. Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 Cells. Ueda K; Hosokawa M; Iwakawa S Biol Pharm Bull; 2015; 38(8):1113-9. PubMed ID: 26235575 [TBL] [Abstract][Full Text] [Related]
29. Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway. Zhang Y; Sun L; Sun Y; Chen Y; Wang X; Xu M; Chi P; Xu Z; Lu X Exp Cell Res; 2020 Apr; 389(1):111856. PubMed ID: 31981591 [TBL] [Abstract][Full Text] [Related]
30. Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells. Tanaka S; Hosokawa M; Ueda K; Iwakawa S Biol Pharm Bull; 2015; 38(9):1272-9. PubMed ID: 26179333 [TBL] [Abstract][Full Text] [Related]
31. Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer. Yao Y; Zhao H; Sun Y; Lin F; Tang L; Chen P Tohoku J Exp Med; 2008 Jul; 215(3):267-78. PubMed ID: 18648187 [TBL] [Abstract][Full Text] [Related]
32. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Valdez BC; Li Y; Murray D; Corn P; Champlin RE; Andersson BS Leuk Res; 2010 Mar; 34(3):364-72. PubMed ID: 19732952 [TBL] [Abstract][Full Text] [Related]
33. Establishment and molecular characterization of decitabine-resistant K562 cells. Wen XM; Zhang TJ; Ma JC; Zhou JD; Xu ZJ; Zhu XW; Yuan Q; Ji RB; Chen Q; Deng ZQ; Lin J; Qian J J Cell Mol Med; 2019 May; 23(5):3317-3324. PubMed ID: 30793488 [TBL] [Abstract][Full Text] [Related]
34. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism? Abu Lila AS; Okada T; Doi Y; Ichihara M; Ishida T; Kiwada H Int J Pharm; 2012 Apr; 426(1-2):263-270. PubMed ID: 22310465 [TBL] [Abstract][Full Text] [Related]
35. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. Arnould S; Guichard S; Hennebelle I; Cassar G; Bugat R; Canal P Biochem Pharmacol; 2002 Oct; 64(8):1215-26. PubMed ID: 12234602 [TBL] [Abstract][Full Text] [Related]
36. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells. Zhang Z; Shen C; Zhou F; Zhang Y Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379 [TBL] [Abstract][Full Text] [Related]
37. Poly(C)-binding protein 1 mediates drug resistance in colorectal cancer. Guo J; Zhu C; Yang K; Li J; Du N; Zong M; Zhou J; He J Oncotarget; 2017 Feb; 8(8):13312-13319. PubMed ID: 28076324 [TBL] [Abstract][Full Text] [Related]
38. Polyene phosphatidylcholine overcomes oxaliplatin resistance in human gastric cancer BGC823 cells. Zhang H; Song H; Yuan R; Zhang X; Yu H; Zhao Y; Jiang T Biochem Biophys Res Commun; 2018 Feb; 497(1):108-114. PubMed ID: 29421658 [TBL] [Abstract][Full Text] [Related]
39. The anti-tumour activity of DNA methylation inhibitor 5-aza-2'-deoxycytidine is enhanced by the common analgesic paracetamol through induction of oxidative stress. Gleneadie HJ; Baker AH; Batis N; Bryant J; Jiang Y; Clokie SJH; Mehanna H; Garcia P; Gendoo DMA; Roberts S; Burley M; Molinolo AA; Gutkind JS; Scheven BA; Cooper PR; Parish JL; Khanim FL; Wiench M Cancer Lett; 2021 Mar; 501():172-186. PubMed ID: 33359448 [TBL] [Abstract][Full Text] [Related]
40. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]